CD44v6和EGFR表达对Ⅱ~Ⅲ期宫颈癌新辅助化疗敏感度的预测价值

Predictive Value of CD44v6 and EGFR Expression in Neoadjuvant Chemotherapy Sensitivity of Stage Ⅱ-Ⅲ Cervical Cancer

目的探讨CD44v6和EGFR的表达对Ⅱ~Ⅲ期宫颈癌新辅助化疗(NACT)疗效的预测价值。方法选择经病理确诊的Ⅱ~Ⅲ期宫颈癌患者53例,所有患者均行2周期紫杉醇+铂类的NACT,收集NACT前的宫颈肿瘤病理组织标本,免疫组织化学SP法检测CD44v6和EGFR的表达,并分析其与Ⅱ~Ⅲ期宫颈癌NACT疗效的相关性。结果53例患者中NACT敏感组(CR+PR)38例,NACT不敏感组(SD+PD)15例,不敏感组CD44v6的表达显著高于敏感组(P<0.05);CD44v6的表达在疗效为CR、PR、SD的患者中具有明显差异(P<0.05)。CD44v6对Ⅱ~Ⅲ期宫颈癌NACT疗效的AUC为0.74,P<0.05;与CD44v6低表达组患者相比,高表达组NACT疗效更差(P<0.05)。Pearson检验发现CD44v6和EGFR表达具有相关性(R=0.34,P<0.05)。结论CD44v6和EGFR表达呈正相关。CD44v6高表达可能会降低Ⅱ~Ⅲ期宫颈癌NACT的疗效,CD44v6表达对宫颈癌紫杉醇+铂类NACT疗效有一定预测价值和临床意义。

Objective To explore the predictive value of the expression of CD44v6 and EGFR on the efficacy of neoadjuvant chemotherapy(NACT)in stage Ⅱ-Ⅲ cervical cancer.Methods A total of 53 patients with stage Ⅱ-Ⅲ cervical cancer diagnosed by pathology were selected.All patients received two cycles of paclitaxel+platinum NACT.The pathological tissue samples of cervical tumors before NACT treatment were collected.The expression of CD44v6 and EGFR were detected by the immunohistochemical SP method,and we analyzed their predictive value of NACT in stage Ⅱ-Ⅲ cervical cancer.Results Among the 53 patients,38 were in the NACT effective group(CR+PR),and 15 were in the NACT ineffective group(SD+PD).The expression of CD44v6 in the ineffective group was significantly higher than that in the effective group(P<0.05).The expression of CD44v6 was significantly different in patients with CR,PR,and SD(P<0.05).The AUC of CD44v6 to NACT effect on stage Ⅱ-Ⅲ cervical cancer was 0.74(P<0.05).The patients in the high expression group of CD44v6 had worse efficacy in NACT than those in the low expression group of CD44v6(P<0.05).Pearson test showed that CD44v6 and EGFR expression were correlated(R=0.34,P<0.05).Conclusion High expression of CD44v6 may reduce the efficacy of NACT in stage Ⅱ-Ⅲ cervical cancer,suggesting that the expression of CD44v6 has a certain predictive value and clinical significance in the efficacy of paclitaxel+platinum NACT on cervical cancer.Moreover,CD44v6 is positively correlated with EGFR expression.